- Email: [email protected]
5095093 Protective four amino ACID epitope against plasmodium vivax malaria
329
PATENTABSTRACTS
BB and PDGF-AB isofonns are disclosed. The subject MAbs may be used in the detection or purification of native PDGF or selected PGDF isoforms. In addition, the MAbs may be labeled with an imaging agent and used for in viva diagnostic purposes, or combined with a pharmaceutically acceptable carrier or diluent for use within wound healing compositions,
determining analyte in a stool sample comprises conjugating anti-analyte antibody adhered to a insoluble support with analyte in the clarified sample, and determining the presence and extent of such conjugation. For determining human hemoglobin in a sample of human stool, the aqueous fecal test solution preferably contains a proteinase inhibitor, formaldehyde and an animal albumin.
5994942
DETECTION OF ANTIBODIES BINDING CARBOXYPEPTIDASE IN SERUM OF CANCER PATIENTS Shuichi Hashizume, Katsumi Mochizuki, Yokohama, Japan assigned to Morinaga & Co Ltd The present invention provides a serodiagnosis method for the detection of cancers, which comprises employing an antigen recognizable by a human monoclonal antibody and derived from animals other than human.
5094956 FECAL SAMPLE COMPOSITION
IMMUNOASSAY AND METHOD
5095003 OXYTOCIN AND VASOPRESSIN ANTAGONISTS Michael A Goetz, Lawrence Koupal, Cheryl Schwartz, Jerrold Liesch, Otto D Hensens, Paul Anderson, Roge Freidinger, Douglas J Pettibone assigned to Merck & Co Inc Cyclic peptides are produced by the controlled aerobic fermentation of Streptomyces silvensis, ATTCC No. 53525 or ATCC No. 53526. These compounds are antagonists of oxytocin and are useful in the treatment of preterm labor and vasopressin and are thus useful in the treatment and prevention of disease states wherein vasopressin may be involved, for example congestive heart failure, hypertension, edema and hyponatremia.
Michael A Grow, Vipin Shah assigned to International Immunoassay Laboratories Inc A method for preparing a fecal sample of immunoassay testing comprising the steps of dispersing a sample of from 1 to less than 10 wt. % of a stool sample in an aqueous fecal test solution formulated with one or more preservatives, analyte stabilizing agents and endogenous interference reducing agents. The fecal solids are then permitted to settle to form a liquid phase substantially free from fecal solids, and the clarified liquid phase is removed to provide a test sample free from fecal solids. The fecal test solutions contain suitable stool stabilizers such as buffers and antimicrobial agents, analyte protecting agents such as proteolytic, reductive or oxidative enzyme inhibitors, endogenous assay interfering enzyme inhibitors such as a reducing agent, and non-specific binding inhibitors such as animal proteins. The stool sample should be fresh or be fresh frozen and thawed immediately before dispersion in the buffer solution. The sample is suitable for any solid-phase immunoassay determination of a fecal sample analyte. A method for
5095093 PROTECTIVE FOUR AMINO ACID EPITOPE AGAINST PLASMODIUM VIVAX MALARIA Stephen L Hoffman, Yupi Charoenvit, Trevor R Jones assigned to The United States of America as represented by the Secretary of the Navy A synthetic peptide of the human malaria Plasmodium vivax, containing at least one repeat of a synthetic peptide having the amino acid sequence Ala-Gly-Asp-Arg (AGDR) which is a protective epitope found on the circumsporozoite (CS) protein of the sporozoites of the human maleria Plasmodium vivax. When a monoclonal antibody specific for this four amino acid sequence binds to the CS protein of the P. vivax sporozoite in viva, infection is prevented. Also described are pharmaceutical formulations of these peptides.
PATENTABSTRACTS
BB and PDGF-AB isofonns are disclosed. The subject MAbs may be used in the detection or purification of native PDGF or selected PGDF isoforms. In addition, the MAbs may be labeled with an imaging agent and used for in viva diagnostic purposes, or combined with a pharmaceutically acceptable carrier or diluent for use within wound healing compositions,
determining analyte in a stool sample comprises conjugating anti-analyte antibody adhered to a insoluble support with analyte in the clarified sample, and determining the presence and extent of such conjugation. For determining human hemoglobin in a sample of human stool, the aqueous fecal test solution preferably contains a proteinase inhibitor, formaldehyde and an animal albumin.
5994942
DETECTION OF ANTIBODIES BINDING CARBOXYPEPTIDASE IN SERUM OF CANCER PATIENTS Shuichi Hashizume, Katsumi Mochizuki, Yokohama, Japan assigned to Morinaga & Co Ltd The present invention provides a serodiagnosis method for the detection of cancers, which comprises employing an antigen recognizable by a human monoclonal antibody and derived from animals other than human.
5094956 FECAL SAMPLE COMPOSITION
IMMUNOASSAY AND METHOD
5095003 OXYTOCIN AND VASOPRESSIN ANTAGONISTS Michael A Goetz, Lawrence Koupal, Cheryl Schwartz, Jerrold Liesch, Otto D Hensens, Paul Anderson, Roge Freidinger, Douglas J Pettibone assigned to Merck & Co Inc Cyclic peptides are produced by the controlled aerobic fermentation of Streptomyces silvensis, ATTCC No. 53525 or ATCC No. 53526. These compounds are antagonists of oxytocin and are useful in the treatment of preterm labor and vasopressin and are thus useful in the treatment and prevention of disease states wherein vasopressin may be involved, for example congestive heart failure, hypertension, edema and hyponatremia.
Michael A Grow, Vipin Shah assigned to International Immunoassay Laboratories Inc A method for preparing a fecal sample of immunoassay testing comprising the steps of dispersing a sample of from 1 to less than 10 wt. % of a stool sample in an aqueous fecal test solution formulated with one or more preservatives, analyte stabilizing agents and endogenous interference reducing agents. The fecal solids are then permitted to settle to form a liquid phase substantially free from fecal solids, and the clarified liquid phase is removed to provide a test sample free from fecal solids. The fecal test solutions contain suitable stool stabilizers such as buffers and antimicrobial agents, analyte protecting agents such as proteolytic, reductive or oxidative enzyme inhibitors, endogenous assay interfering enzyme inhibitors such as a reducing agent, and non-specific binding inhibitors such as animal proteins. The stool sample should be fresh or be fresh frozen and thawed immediately before dispersion in the buffer solution. The sample is suitable for any solid-phase immunoassay determination of a fecal sample analyte. A method for
5095093 PROTECTIVE FOUR AMINO ACID EPITOPE AGAINST PLASMODIUM VIVAX MALARIA Stephen L Hoffman, Yupi Charoenvit, Trevor R Jones assigned to The United States of America as represented by the Secretary of the Navy A synthetic peptide of the human malaria Plasmodium vivax, containing at least one repeat of a synthetic peptide having the amino acid sequence Ala-Gly-Asp-Arg (AGDR) which is a protective epitope found on the circumsporozoite (CS) protein of the sporozoites of the human maleria Plasmodium vivax. When a monoclonal antibody specific for this four amino acid sequence binds to the CS protein of the P. vivax sporozoite in viva, infection is prevented. Also described are pharmaceutical formulations of these peptides.